Zheng Zhongwei, director of the National Health Commission’s Science and Technology Development Center, said the vaccine was approved for use on July 22 during an interview with a Chinese state media broadcaster on Saturday.
Zheng told the CCTV-2 program “Dialogue” that the people at high risk for exposure to the virus – including frontline medical staff, epidemic prevention staff, medical staff at fever clinics, and customs and border staff – were eligible for receiving the vaccine.
The vaccine was developed by Sinopharm’s China National Biotec Group Company (CNBG). Phase 3 clinical trials of this vaccine have been conducted in the UAE, Peru, Morocco, and Argentina.
“There are clear provisions in Article 20 of our country’s vaccine law. If a major public health incident occurs, the National Health Commission submits an application for emergency use of vaccines, and the State Food and Drug Administration organizes experts to evaluate and agree with the NHC for emergency use of faxes within a certain scale and within a certain limited time, “Zheng said.
Zheng, who leads the State Council’s Joint Prevention and Control Mechanism’s vaccine research and development team, said the next phase of vaccine delivery could be used to prevent outbreaks of viruses in the fall and winter. occur in an attempt to “establish an immune barrier.”
“Once we have built an immune barrier for medical staff, staff involved in basic functions of the city, such as those in the farming market, transportation, and in some service industry, could be eligible for the vaccine,” Zheng said. “Then the whole operation of the city has a stable guarantee.”
That vaccine – which was jointly developed by the Beijing Institute of Biotechnology, part of the Chinese government’s Academy of Military Medical Sciences, and vaccine company CanSino Biologics – received “military specialty medicine approval” in June from China’s central military commission. The special permit lasts one year and will only apply to military personnel.
China is the world’s largest producer and consumer of vaccines, and can supply more than 1 billion doses of a vaccine annually from 40 manufacturers nationwide, according to the China Human Vaccine Industry Report 2018-2022.
China currently has more candidates for coronavirus vaccines in human trials than any other nation.
.
